Knowledge about and attitudes to Pap smears, cervical cancer and human papillomavirus among women in Slovenia

High-risk human papillomaviruses (HPV) play a vital role in the development of precancerous changes or cancer in the uterine cervix. Prophylactic vaccination has proven to be an effective measure to reduce the incidence of precancerous changes in the uterine cervix and thereby also of cervical cancer. A population investigation was performed in Slovenia with the aim of determining the level of knowledge and awareness of women about cervical cancer, Pap test, HPV infection and preventive vaccination. The investigation was executed by computer-aided telephone inquiry in the period from 5-22 September 2006 on a sample of 500 women aged from 18 to 55 years from all regions of Slovenia. From the results it may be concluded that, in Slovenia, there is an urgent need to provide the lay population and medical community with relevant and accurate information on HPV infection, on early detection of cervical cancer and preventive vaccination.

Knowledge; HPV infection; Pap test; HPV vaccination

[1] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[2]Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V.: “The causal relation between human papillomavirus and cervical cancer”. J. Clin. Pathol., 2002, 55, 244.

[3] Cuschieri K.S., Cubie H.A.: “The role of human papillomavirus testing in cervical screening”. J. Clin. Virol., 2005, 32 (suppl. 1), 534.

[4] Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iverson O.E. et al.: “High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up”. Br. J. Cancer, 2006, 59, 1459.

[5] Harper D.M., Ault K.A., Guiliano A.R., Costa R.L., Andrade R.P., Brown D.R. et al.: “Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial”. Lancet, 2006, 367, 1247.

[6] Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G. et al.: “American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors”. CA Cancer J. Clin., 2007, 57, 7.

[7] Kahn J.A., Slap G.B., Bernstein D.I., Tissot A.M., Kollar L.M., Hillard P.A. et al.: “Personal meaning of human papillomavirus and pap test results in adolescent and young adult women”. Health Psychol., 2007, 26, 192.

[8] Perrin K.K., Daley E.M., Naoom S.F., Packing-Ebuen J.L., Rayko H.L., McFarlane M. et al.: “Women’s reactions to HPV diagnosis: insights from indepth interviews”. Women Health, 2006, 43, 93.

[9]Moreira E.D. Jr, Oliveira B.G., Ferraz F.M., Costa S., Costa Filho J.O., Karic G.: “Knowledge and attitudes about human papillomavirus, PAP smears, and cervical cancer among young women in brazil: implications for health education and prevention”. Int. J. Gynecol. Cancer, 2006, 16, 599.

[10] Lenselink C.H., Gerrits M.M., Melchers W.J., Massuger L.F., van Hamont D., Kekkers R.L.: “Parental acceptance of Human Papillomavirus vaccines”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2007 (Epub ahead of print).

[11] Dempsey A.F., Zimet G.D., Davis R.L., Koutsky L.: “Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV”. Pediatrics, 2006, 117, 1486.

[12] McCree D.H., Sharpe P.A., Brandt H.M., Robertson R.: “Preferences for sources of information about abnormal Pap test and HPV in women tested for HPV”. Prev. Med., 2006, 43, 165.

[13] Caloway C., Jorgensen C.M., Saraiya M., Tsui J.: “A content analysis of news coverage of the HPV vaccine by U.S. newspapers, January 2002-June 2005”. J. Womens Health, 2006, 15, 803.

[14] Aldrich T., Landis S., Garcia S.G., Becker D., Sanhueza P., Higuera A.: “Cervical cancer and the HPV link: identifying areas for education in Mexico City's public hospitals”. Salud Publica mex, 2006, 48, 236.

[15] Sherris J., Friedman A., Wittet S., Davies P., Steben M., Saraiya M.: “Education, training, and communication for HPV vaccines”. Vaccine, 2006, 24 (suppl. 3), S210.

[16] Brabin L., Roberts S.A., Farzaneh F., Kitchener H.C.: “Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes” (abstract). Vaccine, 2006, 24, 3087.